Catapharma (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.85 M
as on 16-11-2024
- Company Age 38 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.55 Cr
as on 16-11-2024
- Revenue 120.68%
(FY 2023)
- Profit 259.67%
(FY 2023)
- Ebitda 284.13%
(FY 2023)
- Net Worth 59.36%
(FY 2023)
- Total Assets -7.79%
(FY 2023)
About Catapharma (India)
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.85 M.
The company currently has active open charges totaling ₹4.55 Cr.
Shrikant Karwa and Manju Karwa serve as directors at the Company.
- CIN/LLPIN
U99999MH1986PTC041424
- Company No.
041424
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Oct 1986
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Catapharma (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shrikant Karwa  | Managing Director | 29-Oct-1986 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manju Karwa | Director | 18-Feb-2021 | Current |
Financial Performance and Corporate Structure Insights of Catapharma (India).
Catapharma (India) Pvt Ltd, for the financial year ended 2023, experienced significant growth in revenue, with a 120.68% increase. The company also saw a substantial improvement in profitability, with a 259.67% increase in profit. The company's net worth Soared by an impressive increase of 59.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Catapharma (India)?
In 2023, Catapharma (India) had a promoter holding of 23.61% and a public holding of 76.39%. The company had 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Catapro Pharmalab Private LimitedActive 1 year 7 monthsShrikant Karwa and Manju Karwa are mutual person
- Dr. Shrikant Karwa FoundationActive 12 years 6 months
Shrikant Karwa and Manju Karwa are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Apr 2021 | ₹2.00 Cr | Open |
Bank Of India Creation Date: 23 Dec 1994 | ₹2.45 Cr | Open |
Dena Bank Creation Date: 27 Jun 1994 | ₹1.00 M | Open |
How Many Employees Work at Catapharma (India)?
Unlock and access historical data on people associated with Catapharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Catapharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Catapharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
